Levodopa-induced dyskinesias in Parkinson's disease: Etiology, impact on quality of life, and treatments

Elmyra V. Encarnacion, Robert A. Hauser

Research output: Contribution to journalReview article

48 Citations (Scopus)

Abstract

Levodopa is the most effective agent to alleviate motor dysfunction in Parkinson's disease but its long-term use is associated with the development of dyskinesias. Although the pathogenic processes behind the development of levodopa-induced dyskinesias are still being elucidated, it appears that chronic administration of this short-lived agent results in nonphysiologic pulsatile stimulation of striatal neurons and abnormal firing patterns in the basal ganglia. Dyskinesias have been associated with decreased quality of life, and a number of methodologies to evaluate severity of dyskinesias are now available. Strategies to avoid, reduce, or eliminate dyskinesias include providing more continuous dopaminergic stimulation, administering an antidyskinetic agent, and surgery. Several new compounds that may provide an antidyskinetic effect are also under investigation.

Original languageEnglish (US)
Pages (from-to)57-66
Number of pages10
JournalEuropean Neurology
Volume60
Issue number2
DOIs
StatePublished - Jul 1 2008

Fingerprint

Dyskinesias
Levodopa
Parkinson Disease
Quality of Life
Corpus Striatum
Basal Ganglia
Neurons

Keywords

  • Dyskinesia
  • Levodopa
  • Management
  • Parkinson's disease
  • Quality of life
  • Treatment

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Levodopa-induced dyskinesias in Parkinson's disease : Etiology, impact on quality of life, and treatments. / Encarnacion, Elmyra V.; Hauser, Robert A.

In: European Neurology, Vol. 60, No. 2, 01.07.2008, p. 57-66.

Research output: Contribution to journalReview article

Encarnacion, Elmyra V. ; Hauser, Robert A. / Levodopa-induced dyskinesias in Parkinson's disease : Etiology, impact on quality of life, and treatments. In: European Neurology. 2008 ; Vol. 60, No. 2. pp. 57-66.
@article{1039c2f610084d50af47b2f3a6c8b0c0,
title = "Levodopa-induced dyskinesias in Parkinson's disease: Etiology, impact on quality of life, and treatments",
abstract = "Levodopa is the most effective agent to alleviate motor dysfunction in Parkinson's disease but its long-term use is associated with the development of dyskinesias. Although the pathogenic processes behind the development of levodopa-induced dyskinesias are still being elucidated, it appears that chronic administration of this short-lived agent results in nonphysiologic pulsatile stimulation of striatal neurons and abnormal firing patterns in the basal ganglia. Dyskinesias have been associated with decreased quality of life, and a number of methodologies to evaluate severity of dyskinesias are now available. Strategies to avoid, reduce, or eliminate dyskinesias include providing more continuous dopaminergic stimulation, administering an antidyskinetic agent, and surgery. Several new compounds that may provide an antidyskinetic effect are also under investigation.",
keywords = "Dyskinesia, Levodopa, Management, Parkinson's disease, Quality of life, Treatment",
author = "Encarnacion, {Elmyra V.} and Hauser, {Robert A.}",
year = "2008",
month = "7",
day = "1",
doi = "10.1159/000131893",
language = "English (US)",
volume = "60",
pages = "57--66",
journal = "European Neurology",
issn = "0014-3022",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Levodopa-induced dyskinesias in Parkinson's disease

T2 - Etiology, impact on quality of life, and treatments

AU - Encarnacion, Elmyra V.

AU - Hauser, Robert A.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Levodopa is the most effective agent to alleviate motor dysfunction in Parkinson's disease but its long-term use is associated with the development of dyskinesias. Although the pathogenic processes behind the development of levodopa-induced dyskinesias are still being elucidated, it appears that chronic administration of this short-lived agent results in nonphysiologic pulsatile stimulation of striatal neurons and abnormal firing patterns in the basal ganglia. Dyskinesias have been associated with decreased quality of life, and a number of methodologies to evaluate severity of dyskinesias are now available. Strategies to avoid, reduce, or eliminate dyskinesias include providing more continuous dopaminergic stimulation, administering an antidyskinetic agent, and surgery. Several new compounds that may provide an antidyskinetic effect are also under investigation.

AB - Levodopa is the most effective agent to alleviate motor dysfunction in Parkinson's disease but its long-term use is associated with the development of dyskinesias. Although the pathogenic processes behind the development of levodopa-induced dyskinesias are still being elucidated, it appears that chronic administration of this short-lived agent results in nonphysiologic pulsatile stimulation of striatal neurons and abnormal firing patterns in the basal ganglia. Dyskinesias have been associated with decreased quality of life, and a number of methodologies to evaluate severity of dyskinesias are now available. Strategies to avoid, reduce, or eliminate dyskinesias include providing more continuous dopaminergic stimulation, administering an antidyskinetic agent, and surgery. Several new compounds that may provide an antidyskinetic effect are also under investigation.

KW - Dyskinesia

KW - Levodopa

KW - Management

KW - Parkinson's disease

KW - Quality of life

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=48349116255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48349116255&partnerID=8YFLogxK

U2 - 10.1159/000131893

DO - 10.1159/000131893

M3 - Review article

C2 - 18480609

AN - SCOPUS:48349116255

VL - 60

SP - 57

EP - 66

JO - European Neurology

JF - European Neurology

SN - 0014-3022

IS - 2

ER -